Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Lin, H-M; Castillo, Lesley; Mahon, Kate; Hoong Chiam, Keng; Yeop Lee, Byeong; Nguyen, Quoc; Boyer, Michael; R. Stockler, Martin; Pavlakis, Nick; Marx, Gavin; Mallesara, Girish; Gurney, Howard; J. Clark, Susan; Swarbrick, Alexander; J. Daly, Roger; G. Horvath, Lisa

doi:10.1038/bjc.2014.181

Public

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Published in British Journal of Cancer • Apr 8, 2014

Authors:

H-M Lin

Lesley Castillo

Kate Mahon

Abstract

BACKGROUND: Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary toxicity. The potential of circulating microRNAs as early bioma...

Subject

Docetaxel

Prostate cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!